<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055221</url>
  </required_header>
  <id_info>
    <org_study_id>RIV-PH-403</org_study_id>
    <nct_id>NCT03055221</nct_id>
  </id_info>
  <brief_title>TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>TRUST-2</acronym>
  <official_title>TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated
      Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study
      RIV-PH-402 were eligible to enroll.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2005</start_date>
  <completion_date type="Actual">February 25, 2014</completion_date>
  <primary_completion_date type="Actual">February 25, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Remodulin in Subjects with PAH as Assessed by the Number of Subjects with Treatment-related Adverse Events.</measure>
    <time_frame>Baseline to each subject's last visit, assessed up to approximately 9 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>Baseline to each subject's last visit, assessed up to approximately 9 years</time_frame>
    <description>The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Long-term Remodulin Therapy on the New York Heart Association (NYHA) Functional Classification</measure>
    <time_frame>Baseline to each subject's last visit, assessed up to approximately 9 years</time_frame>
    <description>The NYHA functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Intravenous Treprostinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous treprostinil was supplied as 1 mg/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remodulin® (Intravenous Treprostinil)</intervention_name>
    <description>Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.</description>
    <arm_group_label>Intravenous Treprostinil</arm_group_label>
    <other_name>Remodulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who were enrolled in and completed Study RIV-PH-402 (TRUST-1)

        Exclusion Criteria:

          -  Subjects who were unblinded for potential rescue therapy in Study RIV-PH-402 and were
             found to be allocated to the Remodulin treatment group were not eligible to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remodulin</keyword>
  <keyword>6-Minute Walk Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
